A Multicenter, Open-label, Randomized, 3-arm, Phase II Profiling Trial of Pharmacokinetics, Pharmacodynamics and Safety of DEB025/Alisporivir in Combination With Ribavirin Therapy in Chronic Hepatitis C Genotype 2 and 3 Treatment naive Patients

Trial Profile

A Multicenter, Open-label, Randomized, 3-arm, Phase II Profiling Trial of Pharmacokinetics, Pharmacodynamics and Safety of DEB025/Alisporivir in Combination With Ribavirin Therapy in Chronic Hepatitis C Genotype 2 and 3 Treatment naive Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2016

At a glance

  • Drugs Alisporivir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Debiopharm; Novartis; Novartis Pharma
  • Most Recent Events

    • 24 Mar 2016 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
    • 16 Sep 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
    • 18 Jun 2014 Planned End Date changed from 1 Feb 2015 to 1 Mar 2015, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top